Reyvow (lasmiditan) is a selective serotonin 5-HT1F receptor agonist used for acute treatment of cluster headaches, which works by targeting neurogenic inflammation and modulating pain signaling pathways in the trigeminal system. By binding to 5-HT1F receptors, it inhibits neurogenic inflammation and reduces pain transmission without causing vasoconstriction, making it a potentially safer alternative to traditional triptans for cluster headache management.